Cubist Systematic Strategies LLC Takes $1.53 Million Position in Tyra Biosciences, Inc. (NASDAQ:TYRA)

Cubist Systematic Strategies LLC purchased a new stake in Tyra Biosciences, Inc. (NASDAQ:TYRA - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 109,748 shares of the company's stock, valued at approximately $1,526,000. Cubist Systematic Strategies LLC owned approximately 0.22% of Tyra Biosciences at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in TYRA. Rhumbline Advisers increased its holdings in shares of Tyra Biosciences by 4.1% during the fourth quarter. Rhumbline Advisers now owns 26,202 shares of the company's stock worth $364,000 after buying an additional 1,027 shares in the last quarter. RA Capital Management L.P. grew its stake in shares of Tyra Biosciences by 2.1% in the fourth quarter. RA Capital Management L.P. now owns 10,637,290 shares of the company's stock worth $147,858,000 after purchasing an additional 220,681 shares during the last quarter. Barclays PLC grew its stake in shares of Tyra Biosciences by 200.5% in the third quarter. Barclays PLC now owns 37,625 shares of the company's stock worth $884,000 after purchasing an additional 25,106 shares during the last quarter. JPMorgan Chase & Co. raised its holdings in shares of Tyra Biosciences by 1.1% during the third quarter. JPMorgan Chase & Co. now owns 368,647 shares of the company's stock valued at $8,667,000 after purchasing an additional 3,896 shares during the period. Finally, Raymond James Financial Inc. acquired a new stake in shares of Tyra Biosciences in the 4th quarter worth about $761,000. 84.14% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research firms recently commented on TYRA. HC Wainwright reaffirmed a "buy" rating and issued a $30.00 price objective on shares of Tyra Biosciences in a report on Monday, March 31st. Wedbush reiterated an "outperform" rating and issued a $30.00 target price on shares of Tyra Biosciences in a research note on Friday, March 28th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of "Buy" and an average price target of $30.83.

Tyra Biosciences Stock Performance

Tyra Biosciences stock traded up $0.13 during trading on Friday, reaching $9.99. The company had a trading volume of 145,379 shares, compared to its average volume of 261,983. The firm's 50-day simple moving average is $9.55 and its 200 day simple moving average is $12.81. Tyra Biosciences, Inc. has a 1-year low of $6.42 and a 1-year high of $29.60. The firm has a market capitalization of $530.37 million, a PE ratio of -6.20 and a beta of 1.17.

Tyra Biosciences (NASDAQ:TYRA - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.47) EPS for the quarter, topping the consensus estimate of ($0.49) by $0.02. Analysts anticipate that Tyra Biosciences, Inc. will post -1.57 EPS for the current year.

Tyra Biosciences Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.